Leerink Partnrs Predicts Myriad Genetics Q2 Earnings

Myriad Genetics, Inc. (NASDAQ:MYGN) – Research analysts at Leerink Partnrs issued their Q2 2026 earnings per share (EPS) estimates for Myriad Genetics in a note issued to investors on Tuesday, February 25th. Leerink Partnrs analyst P. Souda anticipates that the company will post earnings of ($0.02) per share for the quarter. Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Myriad Genetics’ current full-year earnings is ($0.30) per share. Leerink Partnrs also issued estimates for Myriad Genetics’ Q3 2026 earnings at ($0.01) EPS and Q4 2026 earnings at $0.02 EPS.

MYGN has been the topic of a number of other research reports. UBS Group dropped their price objective on shares of Myriad Genetics from $18.00 to $16.00 and set a “neutral” rating on the stock in a report on Tuesday. Morgan Stanley reduced their price objective on Myriad Genetics from $32.00 to $21.00 and set an “equal weight” rating for the company in a research note on Monday, November 18th. Stephens reissued an “equal weight” rating and set a $20.00 price target on shares of Myriad Genetics in a report on Thursday, January 16th. Bank of America cut their price objective on Myriad Genetics from $15.00 to $13.00 and set an “underperform” rating for the company in a research note on Friday, December 13th. Finally, Piper Sandler decreased their target price on shares of Myriad Genetics from $24.00 to $14.00 and set a “neutral” rating on the stock in a research note on Thursday, January 30th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the company. According to MarketBeat.com, Myriad Genetics has a consensus rating of “Hold” and a consensus price target of $22.14.

Myriad Genetics Stock Down 4.2 %

Shares of Myriad Genetics stock opened at $11.07 on Thursday. Myriad Genetics has a twelve month low of $9.76 and a twelve month high of $29.30. The company has a quick ratio of 1.73, a current ratio of 1.90 and a debt-to-equity ratio of 0.05. The company’s 50 day moving average is $13.33 and its 200 day moving average is $19.16. The company has a market cap of $1.01 billion, a price-to-earnings ratio of -8.52 and a beta of 1.88.

Myriad Genetics (NASDAQ:MYGN) last posted its earnings results on Tuesday, February 25th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.12). Myriad Genetics had a negative net margin of 14.09% and a negative return on equity of 4.51%. The company had revenue of $210.60 million for the quarter, compared to the consensus estimate of $210.35 million. During the same quarter in the prior year, the company posted ($0.12) EPS.

Institutional Trading of Myriad Genetics

Several hedge funds have recently modified their holdings of MYGN. Loomis Sayles & Co. L P boosted its holdings in shares of Myriad Genetics by 153.7% in the 3rd quarter. Loomis Sayles & Co. L P now owns 2,189,601 shares of the company’s stock worth $59,973,000 after purchasing an additional 1,326,497 shares during the period. D. E. Shaw & Co. Inc. boosted its stake in shares of Myriad Genetics by 58.1% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,819,814 shares of the company’s stock valued at $24,950,000 after purchasing an additional 668,429 shares in the last quarter. Disciplined Growth Investors Inc. MN raised its position in shares of Myriad Genetics by 21.1% in the 3rd quarter. Disciplined Growth Investors Inc. MN now owns 2,527,435 shares of the company’s stock worth $69,226,000 after acquiring an additional 440,107 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Myriad Genetics by 377.6% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 549,456 shares of the company’s stock valued at $7,533,000 after buying an additional 434,420 shares during the last quarter. Finally, Iron Triangle Partners LP acquired a new stake in Myriad Genetics in the third quarter valued at approximately $11,007,000. 99.02% of the stock is owned by hedge funds and other institutional investors.

About Myriad Genetics

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.